FDA advisory committee recommends six peptides for compounding pharmacies
ABC News reports on an FDA Pharmacy Compounding Advisory Committee meeting reviewing seven peptides for possible addition to the 503A Bulks List, which would allow licensed compounding pharmacies to manufacture them for prescription use. The segment notes current gray-market access via social media for substances like BPC-157 and TB-500, their lack of clinical trials or FDA approval, and physician concerns over safety and efficacy data. The report states the panel voted in favor of making some peptides more accessible despite FDA scientists' advice against it, with the final decision resting with FDA leadership. It references the advisory nature of the vote and the substances' typical overseas sourcing for research purposes only.
Source: ABC News
